First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment


Ozaras R. , Mete B. , Ceylan B., Ozgunes N., Gunduz A., Karaosmanoglu H., ...Daha Fazla

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.26, ss.774-780, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 26 Konu: 7
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1097/meg.0000000000000099
  • Dergi Adı: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
  • Sayfa Sayıları: ss.774-780

Özet

Background Hepatitis B virus (HBV) infection is a health problem worldwide. Current treatment options for chronic hepatitis B (CHB) are nucleoside or nucleotide analogues and pegylated interferons. Tenofovir and entecavir are much more commonly used as they have better efficacy, tolerability, and high genetic barriers to resistance.